echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Potential "first-in-class" new drug approved for clinical use in China

    Potential "first-in-class" new drug approved for clinical use in China

    • Last Update: 2022-01-25
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    TextPharmaceutical Guanlan

    Recently, the website of the Center for Drug Evaluation (CDE) of the State Food and Drug Administration of China announced that a new class 1 drug named PH94B nasal spray has obtained an implied license for clinical trials and is intended to be developed for: adult social anxiety disorder (SAD) anxiety symptoms


    Screenshot source: CDE official website

    Publicly available information indicates that PH94B is a potential "first-in-class", odorless, fast-acting (within about 15 minutes) synthetic neurosteroid nasal spray with the potential to treat a variety of anxiety-related disorders


    It is reported that PH94B is intended for intranasal administration in microgram doses


    Previously, PH94B has achieved positive results in Phase 2 clinical studies


    (Original abridged)

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.